Lotus Pharmaceutical CoTPE:1795 +1.59%76 OCF Yield % is 15.56 as of Jul. 03, 2026, which is 189% above its 10-year median of 5.39. GuruFocus rates TPE:1795 with a GF Score™ of 76/100 and a GF Value™ of NT$446.11 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks better than 89.57% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Lotus Pharmaceutical Co OCF Yield % Related Terms
Lotus Pharmaceutical Co OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co (TPE:1795) has a OCF Yield % of 15.56 as of Jul. 03, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Lotus Pharmaceutical Co and its competitors. This is 189% above median its historical median of 5.39. Over the past decade, Lotus Pharmaceutical Co's OCF Yield % has ranged from 0.07 to 15.58. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #105 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 10.4%.
Is Lotus Pharmaceutical Co's OCF Yield % too high?
Lotus Pharmaceutical Co's current OCF Yield % of 15.56 is 189% above median its 10-year median of 5.39. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 15.58. The Drug Manufacturers industry median OCF Yield % is 3.43. Lotus Pharmaceutical Co's value of 15.56 is 353.6% above this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #105 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lotus Pharmaceutical Co has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #105 out of 1007 companies for OCF Yield %. This places Lotus Pharmaceutical Co in the top 10% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.43. Lotus Pharmaceutical Co's value of 15.56 is 353.6% above this benchmark. Historically, Lotus Pharmaceutical Co's own OCF Yield % has ranged from 0.07 to 15.58 over the past decade. While the company's 10-year median is 5.39 vs. the industry median of 3.43, Lotus Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.43, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current OCF Yield % of 15.56 is 353.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Lotus Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current OCF Yield % is 15.56, which is 189% above median its own 10-year median of 5.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$446.11, compared to a current price of NT$192.00 — trading 57% below its estimated fair value. The current OCF Yield % is 15.56, which is 189% above median its 10-year median of 5.39 and 353.6% above the Drug Manufacturers industry median of 3.43. Lotus Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current OCF Yield % is 15.56 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$192.00 is trading 57% below its estimated GF Value™ of NT$446.11.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
OCF Yield %: 15.56 (189% above median its 10-year median of 5.39)
GF Value™: NT$446.11 vs. price of NT$192.00 (57% below fair value)
Industry Position: 353.6% above the Drug Manufacturers median (#105 of 1007)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
76GF Score
Get the complete analysis for TPE:1795
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
